Why is "Acalabrutinib" trending?
Latest news, Wikipedia summary, and trend analysis.
Trend Analysis
- Ranking position: #
- Date: 2026-03-13 18:00:09
This topic has appeared in the trending rankings 1 time(s) in the past year. While it does not trend frequently, its appearance suggests a renewed or concentrated surge of public interest.
Based on Wikipedia pageviews and search interest, this topic gained significant attention on the selected date.
Trend Insight
This topic is not currently in the ranking.
Wikipedia Overview
Acalabrutinib, sold under the brand name Calquence, is an anti-cancer medication used to treat various types of non-Hodgkin lymphoma, including mantle cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma. It may be used both in relapsed as well as in treatment-naive settings.
Read more on Wikipedia →Related Topics
Trending Topic Today
Search Interest Perspective
-
Efficacy and Safety of First-Line Acalabrutinib Plus Venetoclax Revamps QOL Outcomes in CLL - OncLive
-
FDA Approves Venetoclax (Venclexta) Plus Acalabrutinib (Calquence) for Previously Untreated CLL - Oncology News Central
-
FDA Approves Acalabrutinib Plus Venetoclax for Previously Untreated CLL/SLL - Targeted Oncology
-
CLL/SLL: FDA Approves Combination of Acalabrutinib and Venetoclax - The ASCO Post
-
Acalabrutinib With Venetoclax Approved for Previously Untreated CLL, SLL - Oncology Nurse Advisor
-
Real-World Evidence Backs Acalabrutinib in CLL Care - AJMC
-
Acalabrutinib + Venetoclax Combo Earns FDA Nod for CLL - Medscape
-
FDA approves AbbVie (ABBV) Venclexta and acalabrutinib combination for first-line CLL - MSN
-
FDA Approves Acalabrutinib Combo in Frontline CLL/SLL - CancerNetwork
-
Calquence plus venetoclax approved in the US as first all-oral, fixed-duration combination for patients with chronic lymphocytic leukaemia in the 1st-line setting - AstraZeneca
-
FDA Approves First-Line Acalabrutinib Plus Venetoclax for CLL/SLL - OncLive
-
Zanubrutinib Offers Clinical and Cost Benefits Over Acalabrutinib in R/R CLL - Targeted Oncology
-
Dr Brown on QOL Considerations With Frontline Acalabrutinib/Venetoclax in CLL - OncLive
-
Acalabrutinib a Safe Treatment Avenue for Older, Frail Patients With CLL - Targeted Oncology
-
Dr Shadman on Indirect Data for Zanubrutinib vs Acalabrutinib/Venetoclax in Treatment-Naive CLL - OncLive
-
Assessing Zanubrutinib vs Acalabrutinib Plus Venetoclax in Frontline CLL - OncLive
-
Dr Lamanna on the FDA Approval of Acalabrutinib Plus Venetoclax for CLL - OncLive
-
Acalabrutinib/Rituximab Followed by Brexu-Cel Drives Responses in Untreated High-Risk Mantle Cell Lymphoma - OncLive
-
Acalabrutinib Delivers Strong Responses With Manageable Toxicities in Steroid-Refractory cGVHD - OncLive
-
Late Addition of Obinutuzumab to Acalabrutinib/Venetoclax Maintains Responses, Boosts Safety in Treatment-Naive CLL - OncLive
-
Venetoclax + acalabrutinib approved by the FDA for previously untreated CLL - Lymphoma Hub
-
Frontline acalabrutinib, lenalidomide and rituximab for advanced stage follicular lymphoma with high tumor burden: phase II trial - Nature
-
Frontline Acalabrutinib/Rituximab Followed By Brexu-Cel Shows Synergy and Safety in High-Risk MCL - OncLive
-
Acalabrutinib/Venetoclax sNDA Under FDA Review for Previously Untreated CLL - OncLive
-
Long-Term ECHO Data Support Concurrent Acalabrutinib/BR in MCL - Targeted Oncology
-
Acalabrutinib Plus BR Highlights Evolving First-Line SOC for High-Risk Mantle Cell Lymphoma - OncLive
-
FDA OKs Acalabrutinib/Venetoclax in CLL/SLL - Oncology Nursing News
-
FDA Review Underway for Oral Venetoclax, Acalabrutinib Combo in Untreated CLL - Targeted Oncology
-
Indirect Comparison Associates Zanubrutinib With Improved PFS in Treatment-Naive CLL - OncLive
-
FDA Approves Venetoclax Plus Acalabrutinib for Previously Untreated Adults With CLL - Pharmacy Times
-
Fixed-duration therapy of chronic lymphocytic leukemia with venetoclax and Bruton tyrosine kinase inhibitors: an insight into differences between ibrutinib and acalabrutinib - Nature
-
Zanubrutinib Extends PFS vs Acalabrutinib Plus Venetoclax in Untreated, Low-Risk CLL - OncLive
-
Dr Dreyling on the Efficacy of Frontline Acalabrutinib Plus BR in High-Risk MCL - OncLive
-
FDA Approves Genentech’s Venclexta® Plus Acalabrutinib Combination Regimen for Previously Untreated Chronic Lymphocytic Leukemia - BioSpace
-
In silico analysis of atrial fibrillation and hypertension mechanism of action secondary to ibrutinib/acalabrutinib in chronic lymphocytic leukemia - Nature
-
Indirect Comparison Supports Zanubrutinib Monotherapy in CLL/SLL Care - CancerNetwork
-
Acalabrutinib-Based Regimens Receive European Approval in Frontline CLL - OncLive
-
Acalabrutinib Shows Low Cardiac Toxicity in Clinical, Real-World Data - AJMC
-
FDA Approval of CLL Combo Marks New Era for Leukemia Care - AJMC
-
Efficacy and Cost Savings of Zanubrutinib in High-Risk R/R CLL - AJMC
-
Acalabrutinib Triplet Demonstrates High Response and Manageable Safety in Frontline Follicular Lymphoma - Targeted Oncology
-
Fixed-duration Calquence-based regimens approved in EU for patients with chronic lymphocytic leukaemia in the 1st-line setting - AstraZeneca
-
Zanubrutinib Leads Other BTK Inhibitors Across B-Cell Lymphomas in Meta-Analysis - AJMC
-
Acalabrutinib Plus Lenalidomide and Rituximab Is Safe and Active in Untreated Follicular Lymphoma - OncLive
-
Zanubrutinib is well tolerated and effective in acalabrutinib-intolerant patients with B-cell malignancies: A long-term follow-up - OncLive
-
ELEVATE-TN 6-year follow-up: Acalabrutinib + obinutuzumab in TN CLL - Lymphoma Hub
-
Dr Munir on the Efficacy of First-Line Zanubrutinib vs Acalabrutinib Plus Venetoclax in CLL - OncLive
-
FDA Approves Combination Treatment of VENCLEXTA (venetoclax) and Acalabrutinib for Previously Untreated Patients With CLL - Oncodaily
-
FDA Approves Calquence Plus Venclexta for CLL and SLL - Cure Today
-
Cross-Trial Analysis Finds Zanubrutinib Outperforms Other BTKis in R/R CLL - Targeted Oncology
-
Dr Khan on the Role of Acalabrutinib in the Current CLL Treatment Paradigm - OncLive
-
"Our Responsibility Should Be to Give You the Closest Thing to a Normal Life" - AJMC
-
Dr Dreyling on Prior Findings From the ECHO Trial of Acalabrutinib Plus BR in Pretreated MCL - OncLive
-
Number needed to treat to avoid progression and death and cost analysis: zanubrutinib versus acalabrutinib in relapsed/refractory chronic lymphocytic leukemia - Oncology Central
-
Indirect Comparison Finds Zanubrutinib Associated With Better PFS, OS Than Acalabrutinib in MCL - AJMC
-
Clinical Practice Insights: Comparing the Safety Profiles of Acalabrutinib, Ibrutinib, and Zanubrutinib - OncLive
-
Exploring Toxicities Driving BTK Inhibitor Selection in R/R CLL - Targeted Oncology
-
European Commission approves fixed-duration acalabrutinib + venetoclax ± obinutuzumab for adult patients with previously untreated CLL - Lymphoma Hub
-
Acalabrutinib: A Favorable Safety Profile in BTK Inhibition - Targeted Oncology
-
FDA OKs Novel Fixed-Duration Oral Combo for Untreated CLL - MedPage Today
-
Cryptococcal Infection in a Patient With Chronic Lymphocytic Leukaemia Receiving Acalabrutinib, a Bruton’s Tyrosine Kinase Inhibitor: A Case Report - Cureus
-
AbbVie wins FDA nod for Venclexta-acalabrutinib combo in first-line chronic lymphocytic leukemia - MSN
-
Acalabrutinib Demonstrates Improved Safety, Survival to Chemoimmunotherapy in CLL - Pharmacy Times
-
COVID-19 Deaths Cloud Interpretation of Acalabrutinib-Venetoclax Combo Results - AJMC
-
ECHO trial 50-month follow-up results: ABR vs PBR in TN MCL - Lymphoma Hub
-
AbbVie Submits sNDA to FDA for Venclexta-Acalabrutinib Combo in Frontline CLL - Applied Clinical Trials Online
-
FDA Approves AbbVie (ABBV) VENCLEXTA and Acalabrutinib Combination for First-Line CLL - Yahoo Finance
-
Acalabrutinib + bendamustine + rituximab in high-risk MCL: A subgroup analysis of the phase III ECHO trial - Lymphoma Hub
-
sNDA Submitted to FDA for Venetoclax Plus Acalabrutinib in Untreated CLL - CancerNetwork
-
How Do Second-Generation BTKi Discontinuation Rates Vary Among Older Adults With CLL? - Cancer Nursing Today
-
Comparative Efficacy of Zanubrutinib vs Fixed-Duration Acalabrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL): A Matching-Adjusted Indirect Comparison (MAIC) - OncLive
-
Indirect Comparison Shows Zanubrutinib Outperforms Acalabrutinib/Venetoclax in Frontline CLL - OncLive
-
Expert Perspectives: Sequencing Strategies After Acalabrutinib + Venetoclax +/- Obinutuzumab as First-Line Therapy in CLL - OncLive
-
Acalabrutinib in treatment of patients with chronic lymphocytic leukemia including those at high genetic risk - Via Medica Journals
-
The OncFive: Top Oncology Articles for the Week of 2/15 - OncLive
-
AbbVie Submits for U.S. FDA Approval of Combination Treatment of VENCLEXTA® (venetoclax) and Acalabrutinib for Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL) - PR Newswire
-
EC approves AstraZeneca’s acalabrutinib combo for CLL - Pharmaceutical Technology
-
MRD Negativity Is Prognostic for Survival and Maintained With Frontline Acalabrutinib/BR in MCL - OncLive
-
First-line treatment for CLL in the era of targeted therapy - Nature
-
Frontline Treatment Discontinuation Is Higher in the Real World vs Clinical Trials in CLL/SLL - OncLive
-
Zanubrutinib Outperforms Acalabrutinib in Adjusted Head-to-Head Analysis - Pharmacy Times
-
Acalabrutinib/Venetoclax With or Without Obinutuzumab Earns Positive CHMP Opinion for Untreated CLL - OncLive
-
Acalabrutinib Combo Receives EU Approval for Mantle Cell Lymphoma - CancerNetwork
-
Acalabrutinib Gains Landmark EU Approval in First-Line MCL - Targeted Oncology
-
MAIC Analysis Shows PFS Favorability With Zanubrutinib vs Acalabrutinib/Venetoclax in CLL - OncLive
-
Optimising treatment strategies in older patients with mantle cell lymphoma - The Lancet
-
Acalabrutinib Plus BR Wins EU Approval for Previously Untreated, Transplant-Ineligible Mantle Cell Lymphoma - OncLive
-
EMA approves acalabrutinib combination for patients with previously untreated MCL - Lymphoma Hub
-
Lower Risk of Cardiovascular Events With Acalabrutinib vs Ibrutinib in CLL in Real-World Study - AJMC
-
AbbVie wins FDA nod for leukemia therapy (update) (ABBV:NYSE) - Seeking Alpha
-
Real-World Study Shows Highest Treatment Adherence Rates With Zanubrutinib vs Other BTK Inhibitors in MCL - OncLive
-
AstraZeneca's fixed-duration Calquence combo wins FDA nod as BeOne CLL rivalry heats up - Fierce Pharma
-
Calquence plus chemoimmunotherapy approved in the EU as first and only BTK inhibitor for 1st-line mantle cell lymphoma - AstraZeneca
-
FDA Clears All-Oral Doublet for First-Line CLL/SLL - Clinical Oncology News
-
Roche - FDA Approves Genentech’S Venclexta Plus Acalabrutinib Combination Regimen - TradingView
-
FDA approves first all-oral, fixed-duration option for CLL - Stock Titan
-
Efficacy of Zanubrutinib Versus Acalabrutinib in the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia (R/R CLL): A Matching-Adjusted Indirect Comparison (MAIC) - OncLive
-
Choosing First-Line CLL Therapy in a Patient With Del(17p), TP53 - Targeted Oncology
-
Second-Generation BTK Inhibitors Set the Stage for Future Advances in CLL Management - OncLive
-
Calquence Plus Venclexta: FDA Approves First All‑Oral Fixed‑Duration Regimen for Adults With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma - WebMD
Why This Topic Is Trending
This topic has recently gained attention due to increased public interest. Search activity and Wikipedia pageviews suggest growing global engagement.
Search Interest & Related Topics
Search interest data over the past 12 months indicates that this topic periodically attracts global attention. Sudden spikes often correlate with major news events, public statements, or geopolitical developments.